Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.1
3.7
Journals
Pathogens
Special Issues
Optimizing Treatment for Parasitic Infections
share announcement

Optimizing Treatment for Parasitic Infections

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Parasitic Pathogens".

Deadline for manuscript submissions: closed (15 April 2023) | Viewed by 9445

Special Issue Editors

Dr. Fernando Salvador

E-Mail Website
Guest Editor
1. Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain
2. PROSICS (Catalan International Health Program), Barcelona, Spain
Interests: Strongyloidiasis, soil-transmitted helminths, schistosomiasis
Dr. Israel Molina

E-Mail Website
Co-Guest Editor
Renê Rachou Research Institute, Fiocruz Minas, Belo Horizonte, Minas Gerais, Brazil
Interests: Chagas disease; leishmaniasis

Special Issue Information

Dear Colleagues,

Parasitic infections affect millions of people worldwide. Some of them are included in the Neglected Tropical Diseases (NTDs) defined by the World Health Organization (e.g., Chagas disease, leishmaniasis, cysticercosis, Guinea Worm, echinococcosis, fascioliasis, sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, and soil-transmitted helminths). NTDs are a group of diseases that cause illness for more than one billion people globally, affecting the poorest populations, and causing high morbidity and mortality. Despite the high prevalence and worldwide distribution of parasitic diseases, little progress has been made in the therapeutic approach to these infections in the last decades. The aim of this Special Issue is to gather information regarding new advances in the treatment of parasitic diseases (especially, but not only, those included in the NTDs), including new drugs, therapeutic schemes, adverse events, cure biomarkers, treatment in specific populations (pregnant women, children, immunosuppressed patients). We invite you to consider contributing to this Special Issue on parasitic infection treatment, which will bring novel information that could potentially have an impact on the health status of millions of affected patients.

We are looking forward to hearing from you.

Dr. Fernando Salvador
Guest Editors
Dr. Israel Molina
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • parasitic infections
  • treatment
  • neglected tropical diseases
  • protozoa
  • helminths
  • Chagas disease
  • leishmaniasis
  • cysticercosis
  • Guinea Worm
  • echinococcosis
  • fascioliasis
  • sleeping sickness
  • lymphatic filariasis
  • onchocerciasis
  • schistosomiasis
  • soil-transmitted helminthes
  • strongyloidiasis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

15 pages, 2997 KiB  
Article
Ginger Is a Potential Therapeutic for Chronic Toxoplasmosis
by Asmaa M. El-kady, Wafa Abdullah I. Al-Megrin, Iman A. M. Abdel-Rahman, Eman Sayed, Eman Abdullah Alshehri, Majed H. Wakid, Fadi M. Baakdah, Khalil Mohamed, Hayam Elshazly, Hussah M. Alobaid, Safa H. Qahl, Hatem A. Elshabrawy and Salwa S. Younis
Pathogens 2022, 11(7), 798; https://doi.org/10.3390/pathogens11070798 - 15 Jul 2022
Cited by 5 | Viewed by 4041
Abstract
Background:Toxoplasma gondii (T. gondii) is an opportunistic parasite that causes serious diseases in humans, particularly immunocompromised individuals and pregnant women. To date, there are limited numbers of therapeutics for chronic toxoplasmosis which necessitate the discovery of effective and safe therapeutics. [...] Read more.
Background:Toxoplasma gondii (T. gondii) is an opportunistic parasite that causes serious diseases in humans, particularly immunocompromised individuals and pregnant women. To date, there are limited numbers of therapeutics for chronic toxoplasmosis which necessitate the discovery of effective and safe therapeutics. In the present study, we aimed to evaluate the antitoxoplasmosis potential of ginger extract in mice with experimentally induced chronic toxoplasmosis. Results: Treatment with ginger extract significantly reduced cysts count in the brains of T. gondii-infected mice with a marked alleviation of edema and inflammation, and a reversal of neuronal injury. Moreover, ginger extract treatment reduced inflammation in liver and lungs and protected hepatocytes from infection-induced degeneration. Consistently, apoptosis was significantly mitigated in the brains of ginger extract-treated mice compared to infected untreated animals or spiramycin-treated animals. Methods: Four groups of Swiss albino mice (10 mice each) were used. The first group was not infected, whereas 3 groups were infected with Me49 T. gondii strains. One infected group remained untreated (infected untreated), whereas the other two infected groups were treated with either ginger extract (250 mg/kg) or spiramycin (positive control; 100 mg/kg), respectively. The therapeutic potential of ginger extract was evaluated by calculation of the parasite burden in infected animals, and examination of the infected tissues for reduced pathologic changes. Conclusions: Our results showed for the first time that ginger extract exhibited marked therapeutic effects in mice with chronic T. gondii infection which indicates that it can be used as a safe and effective treatment for chronic toxoplasmosis. Full article
(This article belongs to the Special Issue Optimizing Treatment for Parasitic Infections)
►▼ Show Figures

Figure 1

10 pages, 1320 KiB  
Article
Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
by Kátia da Silva Fonseca, Luísa Perin, Nívia Carolina Nogueira de Paiva, Beatriz Cristiane da Silva, Thays Helena Chaves Duarte, Flávia de Souza Marques, Guilherme de Paula Costa, Israel Molina, Rodrigo Correa-Oliveira, Paula Melo de Abreu Vieira and Cláudia Martins Carneiro
Pathogens 2021, 10(6), 729; https://doi.org/10.3390/pathogens10060729 - 09 Jun 2021
Cited by 3 | Viewed by 2134
Abstract
As the development of new drugs for Chagas disease is not a priority due to its neglected disease status, an option for increasing treatment adherence is to explore alternative treatment regimens, which may decrease the incidence of side effects. Therefore, we evaluated the [...] Read more.
As the development of new drugs for Chagas disease is not a priority due to its neglected disease status, an option for increasing treatment adherence is to explore alternative treatment regimens, which may decrease the incidence of side effects. Therefore, we evaluated the efficacy of different therapeutic schemes with benznidazole (BNZ) on the acute and chronic phases of the disease, using mice infected with strains that have different BNZ susceptibilities. Our results show that the groups of animals infected by VL-10 strain, when treated in the chronic phase with a lower dose of BNZ for a longer period of time (40 mg/kg/day for 40 days) presented better treatment efficacy than with the standard protocol (100 mg/kg/day for 20 days) although the best result in the treatment of the animals infected by the VL-10 strain was with100 mg/kg/day for 40 days. In the acute infection by the Y and VL-10 strains of T. cruzi, the treatment with a standard dose, but with a longer time of treatment (100 mg/kg/day for 40 days) presented the best results. Given these data, our results indicate that for BNZ, the theory of dose and time proportionality does not apply to the phases of infection. Full article
(This article belongs to the Special Issue Optimizing Treatment for Parasitic Infections)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research

8 pages, 248 KiB  
Study Protocol
Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
by Fernando Salvador, Ana Lucas-Dato, Silvia Roure, Marta Arsuaga, Asunción Pérez-Jacoiste, Magdalena García-Rodríguez, José A. Pérez-Molina, Dora Buonfrate, José María Saugar and Israel Molina
Pathogens 2021, 10(7), 812; https://doi.org/10.3390/pathogens10070812 - 27 Jun 2021
Cited by 4 | Viewed by 2517
Abstract
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to [...] Read more.
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients. Full article
(This article belongs to the Special Issue Optimizing Treatment for Parasitic Infections)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop